StockData
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. (TPST) stock

TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.31−0.02 (-5.50%)

Close on Nov 18, 2026Market cap $4.58MP/E –Yield –

Tempest Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Tempest Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$20.73M. For fiscal 2025 it was -$26.82M. The highest annual figure on record is -$12.01M in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$26.82M–
FY2024Dec 31, 2024-$33.46M–
FY2023Dec 31, 2023-$27.53M–
FY2022Dec 31, 2022-$31.63M–
FY2021Dec 31, 2021-$26.09M–
FY2020Dec 31, 2020-$19.07M–
FY2019Dec 31, 2019-$41.62M–
FY2018Dec 31, 2018-$23.68M–
FY2017Dec 31, 2017-$20.34M–
FY2016Dec 31, 2016-$64.32M–
FY2015Dec 31, 2015-$55.52M–
FY2014Dec 31, 2014-$33.39M–
FY2013Dec 31, 2013-$18.81M–
FY2012Dec 31, 2012-$12.01M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.78M–
Q1 FY2026Mar 31, 2026-$7.60M–
Q4 FY2025Dec 31, 2025-$3.57M–
Q3 FY2025Sep 30, 2025-$6.78M–
Q2 FY2025Jun 30, 2025-$8.43M–
Q1 FY2025Mar 31, 2025-$8.04M–
Q4 FY2024Dec 31, 2024-$10.15M–
Q3 FY2024Sep 30, 2024-$10.20M–
Q2 FY2024Jun 30, 2024-$5.76M–
Q1 FY2024Mar 31, 2024-$7.35M–
Q4 FY2023Dec 31, 2023-$6.18M–
Q3 FY2023Sep 30, 2023-$6.49M–
Q2 FY2023Jun 30, 2023-$6.51M–
Q1 FY2023Mar 31, 2023-$8.35M–
Q4 FY2022Dec 31, 2022-$6.84M–
Q3 FY2022Sep 30, 2022-$9.18M–
Q2 FY2022Jun 30, 2022-$8.51M-15028.1%
Q1 FY2022Mar 31, 2022-$7.11M–
Q4 FY2021Dec 31, 2021-$8.01M–
Q3 FY2021Sep 30, 2021-$11.81M–
Q2 FY2021Jun 30, 2021$57.00K+96.6%
Q1 FY2021Mar 31, 2021-$6.32M–
Q4 FY2020Dec 31, 2020-$4.28M–
Q3 FY2020Sep 30, 2020-$4.63M–
Q2 FY2020Jun 30, 2020$29.00K–
Q1 FY2020Mar 31, 2020-$10.19M–
Q4 FY2019Dec 31, 2019-$11.72M–
Q3 FY2019Sep 30, 2019-$8.44M–
Q2 FY2019Jun 30, 2019-$10.84M–
Q1 FY2019Mar 31, 2019-$10.61M–
Q4 FY2018Dec 31, 2018-$9.24M-153.3%
Q3 FY2018Sep 30, 2018-$4.74M–
Q2 FY2018Jun 30, 2018-$4.71M–
Q1 FY2018Mar 31, 2018-$5.00M–
Q4 FY2017Dec 31, 2017$17.35M–
Q3 FY2017Sep 30, 2017-$10.32M–
Q2 FY2017Jun 30, 2017-$12.12M–
Q1 FY2017Mar 31, 2017-$15.26M–
Q4 FY2016Dec 31, 2016-$16.51M–
Q3 FY2016Sep 30, 2016-$15.61M–

More Tempest Therapeutics figures

See a number that looks wrong?